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BACKGROUND & AIMS:
Chronic intestinal pseudoobstruction (CIPO) is characterized by severe intestinal dysmotility that mimics a mechanical subocclusion with no evidence of gut obstruction. We searched for genetic variants associated with CIPO to increase our understanding of its pathogenesis and to identify potential biomarkers. METHODS: We performed whole-exome sequencing of genomic DNA from patients with familial CIPO syndrome. Blood and lymphoblastoid cells were collected from patients and controls (individuals without CIPO); levels of messenger RNA (mRNA) and proteins were analyzed by quantitative reverse-transcription polymerase chain reaction, immunoblot, and mobility shift assays. Complementary DNAs were transfected into HEK293 cells. Expression of rad21 was suppressed in zebrafish embryos using a splice-blocking morpholino (rad21a). Gut tissues were collected and analyzed. RESULTS: We identified a homozygous mutation (p.622, encodes Ala>Thr) in RAD21 in patients from a consanguineous family with CIPO. Expression of RUNX1, a target of RAD21, was reduced in cells from patients with CIPO compared with controls. In zebrafish, suppression of rad21a reduced expression of runx1; this phenotype was corrected by injection of human RAD21 mRNA, but not with the mRNA from the mutated p.622 allele. rad21a Morpholino zebrafish had delayed intestinal transit and greatly reduced numbers of enteric neurons, similar to patients with CIPO. This defect was greater in zebrafish with suppressed expression of ret and rad21, indicating their interaction in the regulation of gut neurogenesis. The promoter region of APOB bound RAD21 but not RAD21 p.622 Ala>Thr; expression of wild-type RAD21 in HEK293 cells repressed expression of APOB, compared with control vector. The gut-specific isoform of APOB (APOB48) is overexpressed in sera from patients with CIPO who carry the RAD21 mutation. APOB48 also is overexpressed in sporadic CIPO in sera and gut biopsy specimens. CONCLUSIONS: Some patients with CIPO carry mutations in RAD21 that disrupt the ability of its product to regulate genes such as RUNX1 and APOB. Reduced expression of rad21 in zebrafish, and dysregulation of these target genes, disrupts intestinal transit and the development of enteric neurons.
Keywords: Sporadic and Familial Chronic Intestinal Pseudoobstruction; Intestinal Motility; Animal Model; Genetic Analysis. C hronic intestinal pseudo-obstruction (CIPO), a rare and potentially life-threatening disorder with unknown prevalence and incidence, [1] [2] [3] is viewed typically as an insufficiency of the intestinal peristalsis that mimics a subocclusive disease in the absence of mechanical obstructions. [4] [5] [6] The severity of the clinical presentation and the limited understanding of the disorder contribute to poor quality of life and increased mortality. 2, [4] [5] [6] [7] In addition, there are no specific biochemical or molecular biomarkers of CIPO, further hindering a correct diagnosis. From a genetic perspective, most patients with CIPO experience sporadic occurrences, although X-linked, autosomal-dominant, and recessive forms have been identified with mutations in filamin A, 8, 9 actin G2, 10 thymidine phosphorylase 11 /polymerase g, 12 and, more recently, in SGOL1. 13 However, the underlying genetic alterations and molecular mechanisms remain unknown in most CIPO cases.
We previously mapped a locus in a large consanguineous family, segregating an autosomal-recessive form of CIPO. 14, 15 In the affected family members, the major clinical feature was represented by CIPO, in addition to megaduodenum, long-segment Barrett esophagus, and cardiac abnormalities of variable severity (OMIM 611376; Mungan syndrome). Here, we intersected mapping data with whole-exome sequencing to identify RAD21 as a causal locus for CIPO. Our combined genetic and functional data suggest a loss-offunction mechanism that disrupts the structure and function of enteric innervation. Moreover, based on our previous observations that identified apolipoprotein B (APOB) as a target of RET signaling, 16 we explored the role of this protein in CIPO etiopathology in the context of RAD21 mutations. Here, we report a key role for APOB48, a gut-specific isoform, 17 as a transcriptional target of RAD21, and thus a contributor to CIPO, with potential utility as a biomarker.
Materials and Methods

Patients and Controls
The clinical characteristics of the patients with syndromic CIPO are indicated in the Supplementary Material and Methods section. An additional 21 Italian and 12 Swedish sporadic patients with idiopathic CIPO were included in the study (8 men and 25 women; mean age, 38.6 ± 16.6 y). Table 1 shows the major clinical characteristics of these patients. Five hundred Turkish controls were recruited at the Universities of Ankara and Istanbul; 240 controls of European ancestry were recruited at the University of Bologna. All data from patients and controls, including informed consent, were handled in accordance with local ethical committee-approved protocols and in compliance with the Helsinki declaration (http://snp.gs. washington.edu/SeattleSeqAnnotation137).
High-Throughput Single-Nucleotide Polymorphism Genotyping and Whole-Exome Sequencing Analysis
A detailed description of the single-nucleotide polymorphism (SNP) genotyping and whole-exome sequencing analysis is reported in the Supplementary materials. Variant detection and genotyping were annotated with the SeattleSeq137 Annotation Server.
RAD21 Mutation Screening in Idiopathic CIPO Cases
Genomic DNA extracted from peripheral blood was amplified as reported in the Supplementary materials.
RAD21
Complementary DNA Transfection Into HEK293 Cells HEK293 cells (3 Â 10 5 ) were plated for transfection of the different plasmids using liposomes as described in the Supplementary materials.
Gene Expression Analysis
Total RNA from 1.5 mL fresh blood was extracted with the Qiagen Blood Total RNA kit (Qiagen, Venlo, Limburg, The Netherlands). Total RNA from lymphoblastoid or transfected cells was extracted with the RNeasy kit (Qiagen). Real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) was performed as reported in the Supplementary materials.
Zebrafish Functional Assays
To determine the effect of rad21a suppression in zebrafish embryos, a splice-blocking morpholino (MO) was designed as described in the Supplementary materials. A published ret MO was used. 18 To measure rad21a MO efficiency, total messenger RNA (mRNA) was extracted from control and MO-injected embryos, reverse-transcribed, and the site targeted by the MO was PCR-amplified (Supplementary Figure 1) . runx1 expression analysis and enteric nervous system characterization are reported in the Supplementary materials.
Microgavage
Control and rad21 MO-injected embryos were developed until 5 days postfertilization (dpf). Zebrafish larvae were anesthetized in Tricaine (Sigma, St. Louis, MO), mounted in 3% methylcellulose, and injected with fluorescent beads into the mouth as described. 19 
Electromobility Shift Assay
LCLs (2 Â 10 6 ) were processed for nuclear extract preparation as described in the Supplementary materials.
Immunoprecipitation and Western Blotting
Lymphoblastoid cell lines (LCLs) (2 Â 10 6 ) were used for immunoprecipitation assays. Crude sera of patients was diluted in phosphate-buffered saline. Serial dilutions for cases and controls were performed (1:5, 1:10, and 1:100) (Supplementary Figure 2A) . Immunoprecipitation and Western blotting were performed as reported in the Supplementary materials.
Immunohistochemistry
Immunohistochemistry was performed as reported in the Supplementary materials. Incubation with the corresponding blocking peptides or with the secondary antibodies only were performed as negative controls (Supplementary Figure 2B and C).
Quantitative Evaluation of Ganglion Cells
Quantitative evaluation of neuron number in myenteric and submucosal ganglia was performed according to Ganns et al 20 (Supplementary materials).
Statistical Analysis
A case-control association study for SNP rs72105712 was performed using Haploview 4.0 (http://www.broadinstitute. org/scientific-community/science/programs/medical-and-pop ulation-genetics/haploview/). A statistical analysis of quantitative differences was performed using the Student t test from the GraphPad package (http://graphpad.com/quickcalcs/). A fluorescent cell count was performed with ImageJ (National Institutes of Health, Bethesda, MD) (http://rsbweb.nih.gov/ij); chi-squared tests were calculated using the dedicated option from GraphPad.
Results
Identification of a Novel RAD21 Mutation in CIPO
We performed a combined SNP-genotyping/next generation-sequencing approach in a consanguineous CIPO pedigree of Turkish origin ( Figure 1A ), in which we previously mapped a linkage locus with a multipoint logarithm (base 10) of odds score of 5.019. 14 Table 1) . We then performed whole-exome sequencing on genomic DNA from 2 affected individuals (IV-9 and IV-11) ( Figure 1A ). We filtered data for variants that were (1) homozygous in our patients; (2) rare (minor allele frequency [MAF] <1%) in public databases (Exome Variant Server, Database of Short Genetic Variations); and (3) predicted computationally to be pathogenic. We found a single variant that fulfilled all these conditions inside our linkage interval on chromosome 8 ( Figure 1 and Supplementary Figure 3A) . This homozygous allele affects the coding change c. 1864 G>A in RAD21 (NM_006265.2), and is predicted to generate a missense substitution p.622 Ala>Thr ( Figure 1B ). Mutation Taster (http://www.mutationtaster.org/) and PolyPhen-2 (http:// genetics.bwh.harvard.edu/pph2/) 21 analysis predicted this change to be "disease causing" and "damaging," respectively (Mutation Taster P ¼ .9999; PolyPhen-2 HumDiv score, 0.999; sensitivity, 0.14; specificity, 0.99; HumVar score, 0.993; sensitivity, 0.47; specificity, 0.96), and the variant was absent from public databases (dbSN: www.ncbi.nlm.nih.gov/SNP/; 1000 Genomes: www.1000genomes.org/; NHLBI Exome Sequencing Project (ESP): http://evs.gs.washington.edu/EVS/), and from 1000 control chromosomes of Turkish origin analyzed by our group. To test the candidacy of this allele, we performed a segregation analysis on all available family members: all 3 affected siblings carried the change in a homozygous state and all carriers of the risk haplotype (including the parents) were heterozygous ( Figure 1A ).
To evaluate whether RAD21 mutations also were prevalent in other idiopathic CIPO cases, we screened 21 Italian and 12 Swedish individuals with pseudo-obstruction, defined by clinical, manometric, and radiologic examination (Table 1) . We did not identify any mutation in the RAD21 coding region, although a 1-bp indel was detected with high frequency in the upstream region (MAF, 0.364; g.11788122-11788123 ins[C]; rs72105712 [dbSNP137]). Because no allele frequencies were known for this SNP, we investigated the frequency in a control group of European ancestry (N ¼ 240); we found no differences between cases and controls (MAF, 0.36 in cases and 0.34 in controls; c 2 ¼ 0.08; P ¼ .77).
Mutant RAD21 p.622 Ala>Thr Alters RUNX1 Expression
To test the candidacy of RAD21 further, we evaluated its expression in blood and LCLs obtained from 1 homozygous patient and several controls, including 1 unaffected wildtype brother. Real-time quantitative RT-PCR showed that RAD21 expression in the affected individual was comparable with that in controls, either in blood (Supplementary Figure 3B ) or in LCL complementary DNA (cDNA) (Supplementary Figure 3C) . The mutant protein also was expressed in LCLs in amounts comparable with wild-type cells (Supplementary Figure 3D , upper panel). Likewise, testing the interaction of RAD21 with SMC1, one of its known partners, 22 in co-immunoprecipitation experiments showed that the mutant protein still retains SMC1-binding activity (Supplementary Figure 3D , middle panel).
Because one of the main target genes activated by RAD21 is RUNX1 23, 24 we investigated whether mutated RAD21 could hamper its transcription activity. Indeed, the affected individual's LCLs showed significantly reduced RUNX1 expression compared with controls ( Figure 1C) . Similarly, transfection of mutant RAD21 cDNA in HEK293 cells and subsequent quantitative RT-PCR showed a significant decrease in RUNX1 expression (P ¼ .0028, Student t test) compared with cells transfected with wild-type RAD21 cDNA (Supplementary Figure 3E) .
Rad21a Suppression Causes Down-regulation of runx1 Expression and Loss of Enteric Neurons In Vivo
To test the hypothesis that RAD21 is necessary for enteric development and to assay the pathogenic potential of the newly discovered allele in a physiologically relevant in vivo system, we investigated RAD21 in zebrafish development.
Given our in vitro observations on the role of RAD21 on RUNX1 expression and its down-regulation in patient cells, we asked whether RAD21 can replicate this defect in vivo and whether the patient's mutation has the expected effect. We identified (by reciprocal BLAST) the sole ortholog of RAD21 and we injected zebrafish embryos with a rad21a splice-blocking MO (at 1-2 cell stage; Supplementary  Figure 2A and B). Embryos were fixed at 14 hours postfertilization and stained with a runx1 probe. During zebrafish development, runx1 is expressed in the posterior lateral plate mesoderm. We observed defects in runx1 expression patterns recapitulating prior studies, 23, 24 with runx1 expression either partially or completely absent in rad21a morphants (Figure 2A -C). Runx1 expression was rescued by co-injection of MO with human WT RAD21 mRNA. In contrast, co-injection of MO and mRNA encoding the p.622 Thr allele was not able to rescue runx1 expression, indicating that the RAD21 mutation has a loss-of-function effect in vivo ( Figure 2D ).
To test whether we could recapitulate the CIPO phenotype seen in RAD21 mutant patients, including a severe impairment of gut motility and marked hypoganglionosis, 14 we characterized the zebrafish gut. Subsequent to MO injection, embryos were allowed to develop to 5 dpf, at which time the digestive system had developed. 25 Notably, we saw no appreciable runx1 expression in the gut at this stage of development (data not shown), suggesting an earlier onset of the enteric phenotype. Control and MO embryos were fed fluorescent beads through microgavage, a technique that allows determination of the rate of intestinal motility as a function of time. 19 After 8 hours postbead injection, embryos were divided into 1-4 zones based on anatomic landmarks ( Figure 3A) , and the presence of fluorescence in each segment was scored. Consistent with the CIPO phenotype, rad21a morphants showed delayed food transit along the gut ( Figure 3B ). Moreover, staining of enteric neurons along the gut with antibodies against HuC/D showed significant depletion of enteric neurons ( Figure 3C ). Quantitative analysis of the zebrafish gut ( Figure 3D ) at 4 ( Figure 3D , upper panel) and 5 ( Figure 3D , lower panel) dpf stages showed that rad21 morphants had a marked reduction of HuC/D-immunolabeled enteric neurons compared with controls, suggesting a neurogenic cause of the observed motility defects.
Notably, previous reports on rad21a morphants and rad21 nz171 mutants have shown significantly reduced expression of ascl1a, 26 a neuronal marker. Ascl1 is also a transcription factor that is required for the development of serotonergic neurons. 26 An ASCL1 mutation was reported previously in Haddad syndrome, a condition that encompasses congenital central hypoventilation syndrome and Hirschsprung disease (MIM 209880).
These data, the similarity of rad21a morphants to the hypoganglionic phenotype observed in a mouse model for the ret mutation C620R, 27, 28 raised the possibility that RAD21 and RET might act synergistically during gut neurogenesis. We therefore performed epistasis analysis by coinjecting rad21a and ret MOs at subeffective doses, at which each MO alone was indistinguishable from control embryos. We observed strong epistasis on the innervation of the gut; co-injection of the 2 genes phenocopied the phenotype of high-dose rad21 MOs ( Figure 3E and F) . At the same time, overexpression of RET did not rescue rad21 morphants, or vice versa, suggesting that the 2 genes act on the same process but not directly in the same pathway. This observation was consistent with previous studies that showed RET to be induced by NGF in a runx1-independent manner. 29 The Mutant RAD21 p.622 Ala>Thr Does Not Bind to RAD21-Binding Elements in Apolipoprotein B Promoter
Recent data have shown that RAD21/CTCF binding sites are present in the apolipoprotein A1/C3/A4/A5 gene cluster on chromosome 11 and that altered binding of these factors to these sites dysregulates apolipoprotein expression. 30 We therefore performed electromobility shift assay experiments to test whether the mutant RAD21 protein could retain its binding affinity for the earliermentioned sites, in particular for the AC2 site. 30 We observed no differences between the nuclear extracts from wild-type and mutant LCLs in binding to this site (Supplementary Figure 3F) . Next, we investigated if the nuclear extracts from wild-type and mutant LCLs could show differences in binding to the human APOB promoter. 31 In silico analysis with MatInspector (Genomatix, Munich, Germany) identified 2 binding sites for RAD21/ CTCF (hAPOB_c1, chr2: 21,267,137-21,267,173; matrix score, 0.862; hAPOB_c2, chr2: 21,266,910-21,266,945; matrix score, 0.807), which maps to the 2 regulatory regions of the proximal APOB promoter. 31 Electromobility shift assays performed with probes corresponding to the 2 sites showed a specific shift only in the presence of wildtype nuclear extracts ( Figure 4A ). Moreover, specific supershifts with an anti-RAD21 antibody were detectable only in wild-type, but not in mutant, nuclear extracts (Supplementary Figure 4A) . Transfection of the plasmids carrying either wild-type or mutant RAD21 cDNAs in frame with the DDK-epitope, in HEK293 cells, and subsequent quantitative RT-PCR analysis of APOB expression, showed that wild-type RAD21 overexpression reduced APOB levels compared with the empty vector (P ¼ .0098; Student t test). In contrast, overexpression of the mutant protein had no effect, similarly to the empty-vector transfections ( Figure 4B and C). These data suggest that RAD21 might act as a repressor of APOB.
APOB Is Overexpressed in CIPO Patients
APOB transcript generates 2 different proteins, APOB48 and APOB100 isoforms, both present in serum. 17 Because our data suggested a RAD21-regulated expression of APOB, we analyzed sera from the CIPO patient homozygous for RAD21 mutation (IV-9), and from wild-type controls. We detected an increased expression of APOB48 in the patient, whereas no significant differences could be appreciated for APOB100 ( Figure 5A and Supplementary Figure 5A ). To understand whether APOB overexpression was unique to this patient or whether it might represent a more generalized phenomenon, we evaluated sera from RAD21 mutationnegative idiopathic CIPO patients and from control subjects. CIPO patients showed an increase in APOB48 ( Figure 5B and Supplementary Figure 5B) . Moreover, compared with CIPO, sera derived from 12 patients with functional bowel disease, namely 7 patients with diarrhea-predominant irritable bowel syndrome (IBS), 4 patients with constipationpredominant IBS, and 1 patient with alternating bowel IBS, did not show APOB48 overexpression ( Figure 5C and Supplementary Figure 5C ). Furthermore, Western blot analysis on the sera of patients with other gastrointestinal disorders (ie, anorexia nervosa and mechanical intestinal obstruction), did not identify any APOB48 increase (Bianco et al, data not shown).
Immunohistochemical analysis of gut biopsy specimens (mainly ileum) of sporadic CIPO patients showed APOB48 expression in myenteric neurons and in cells of the lamina propria, reminiscent of immunocytes ( Figure 5 ). Consistent with the results obtained in the sera, the APOB48 signal was increased markedly in the biopsy specimens of CIPO cases compared with controls and IBS cases ( Figures 5D, i-iv-vii) . The quantitative analysis of immunolabeled cells in the lamina propria of 8 CIPO patients (5 Italian and 3 Swedish patients) indicated a significant increase in the number of APOB48-positive cells compared with the other individuals (controls, n ¼ 3; IBS patients, n ¼ 3) (32.9% ± 9.2% vs 7.2% ± 2.5% cases vs controls; P ¼ .0012, Student t test; 32.9% ± 9.2% vs 5.6% ± 1.5% CIPO cases vs IBS cases; P ¼ .0008; CIPO cases [n ¼ 8] vs all [n ¼ 6]; P ¼ .0001) (Figure 5Dv-vii) . In addition, quantitative analysis performed in the gut biopsy specimens of sporadic CIPO patients with a marked increased in APOB48 showed a significant reduction in the number of neuron-specific enolase-labeled myenteric ganglion cell bodies/ganglion compared with control specimens (CIPO cases 22.71 ± 8.10 vs controls 48.65 ± 13.80; P ¼ .0039, Student t test) ( Figure 5E ). No significant differences were observed for neurons in the submucosal plexus between CIPO cases and controls (CIPO cases 5.61 ± 0.39 vs controls 8.36 ± 2.96; P ¼ .1079, Student t test).
We observed RAD21 staining in multiple tissues and throughout different components of the gut, as shown previously (www.proteinatlas.org), although no differences were appreciated between CIPO and controls ( Supplementary Figure 6Ai-iv) . The expression of APO-BEC1, the gut-specific RNA editing enzyme responsible for the formation of the APOB48 isoform, also was investigated; we observed similar immunostaining in control and CIPO tissue biopsy specimens ( Supplementary Figure 6Bi and Bii).
Discussion
This study provides in vitro and in vivo evidence that a novel homozygous mutation in RAD21 is associated with a syndromic form of CIPO. RAD21 is part of the cohesin complex, forms a physical link between SMC1/SMC3 and STAG subunits, and controls sister chromatid pairing and unpairing during cell replication.
32 RAD21 is also a transcriptional regulator that binds to many sites in the genome. 33 In concordance with the key role(s) of RAD21 in regulating cell division, altered expression and somatic lossof-function mutations have been reported in different cancers. 34, 35 Furthermore, heterozygous germline mutations in cohesin subunits (ie, RAD21, SMC1, and STAG), or in regulators of cohesin (eg, NIPBL), cause a broad spectrum of disorders referred to as cohesinopathies (namely, Cornelia de Lange syndrome, OMIM 122470), characterized by facial dysmorphisms, growth retardation, developmental delay and/or intellectual disability, and multiorgan involvement, including musculoskeletal malformations ranging from brachyclinodactyly to severe reduction defects.
36-39
We observed a similar loss-of-function phenotype for 2 missense CdL mutations (p.376Pro>Arg, p.585Cys>Arg) and for our CIPO variant in RAD21 (p.622Ala>Thr). However, in the consanguineous family studied herein the heterozygous carriers of the RAD21 mutation did not show sign of CdLS.
14 Previously described patients with Cornelia de Lange syndrome and different RAD21 heterozygous mutations did not show gastrointestinal abnormalities such as CIPO. 32, 40 It is worth noting that the mutations observed in Cornelia de Lange syndrome and in our CIPO patients map to different RAD21 domains, potentially suggesting that specific mutational mechanisms in RAD21 can lead to different clinical entities in human beings. Consistent with this notion, the CIPO-causing mutations do not appear to abolish the ability of RAD21 to bind to SMC1, whereas it does attenuate its transcriptional repressive role of other targets, such as APOB.
Recently, however, a mutation in SGOL1, another cohesin protein, was associated with severe gut and cardiac dysrhythmia in the absence of other congenital abnormalities or cohesinopathies.
13
RAD21 plays an important role in the development, survival, and maintenance of epithelial cells and neurons of the gastrointestinal tract, and mice heterozygous for a Rad21 null mutation show gastrointestinal defects after X-ray irradiation. 41 Our zebrafish studies suggest that rad21 is essential for enteric neuron development: rad21a morphants recapitulate the CIPO phenotype because they show delayed transit along the gut and a significant depletion of enteric neurons. This latter finding is reminiscent of an enteric neuronal hypoganglionic phenotype observed in heterozygous ret C620R/þ mice 16 and shares similarities with the histopathology of some CIPO patients. 14, 27, 28 The similarity of the rad21 suppression phenotype in zebrafish to the neuronal defects of heterozygous ret C620R/þ mice prompted us to test whether those 2 genes might interact genetically. We showed that RET and RAD21 interact epistatically during differentiation or maintenance of enteric neurons. However, the failure of the 2 genes to rescue the gut innervation phenotype suggests that they activate different molecular pathways.
Our previous studies identified apolipoprotein B (Apob) as a target of RET signaling in Neuro2a cells, a murine model of enteric nervous system development. Moreover, in ret þ/C620R mice that have an enteric neuronal hypoganglionic phenotype 16 reminiscent of the histopathology observed in some CIPO patients, 27, 29 Apob was overexpressed markedly. APOB is a major constituent of the plasma lipoprotein, and in mammals is synthesized in 2 different tissues (ie, liver and intestine). Two different proteins derive from the APOB transcript by a RNA editing enzyme: APOBEC1, the full-length APOB100, a large protein of 512 kilodaltons synthesized by the liver (which does not express APOBEC1), essential for triglyceride-rich very-lowdensity lipoprotein formation; and the gut-specific isoform APOB48, formed via the RNA editing process and co-linear with the N-terminal half of APOB100. APOB48 has a key role in chylomicron assembly and transport in the intestine. APOB expression is regulated by a strong promoter in the proximal upstream region, containing several positive regulatory elements, including one within the noncoding exon 1, but also a negative regulatory element between bases -261 and -129. 31 In this study we identified 2 RAD21 binding sites in the APOB proximal promoter (ie, overlapping the negative element, and the other partially overlapping the exon 1-positive regulatory element). Only nuclear extracts from wild-type cells form a specific complex with either region, whereas no complex is observed in the presence of mutant RAD21. This suggests that RAD21 may act as a repressor of APOB transcription, associating with its negative regulatory element and competing with the transcriptional activators that bind to the positive regulatory element.
17
Finally, we found that, compared with controls, gutspecific APOB48 17 levels were increased in the serum of the RAD21-mutated CIPO patient. Interestingly, sera from the sporadic CIPO patients, negative for RAD21 mutations, also showed consistently increased APOB48 levels compared with either IBS patients or healthy controls. We observed a variable expression of APOB100 in both controls and CIPO patients, in line with the fact that its regulation depends on different factors, including cholesterol and insulin levels. 42 Notably, CIPO patients did not show evidence of altered lipid metabolism (ie, total cholesterol and highdensity lipoprotein levels were within the normal range) (Supplementary Table 2 ).
APOB48 overexpression was corroborated further by the data on gut biopsy specimens from CIPO patients. Compared with controls, APOB48 immunoreactivity was increased significantly in cells (with morphologic features of immunocytes) distributed throughout the lamina propria and in myenteric neurons of CIPO patients.
Interestingly, a recent study identified a specific neuronmacrophage cross-talk in regulating gut motility. 43 These data bear implications to the pathogenesis of functional bowel disorders, such as IBS. However, our study did not show any change in APOB expression in patients with IBS, suggesting that other molecular pathways also can be involved in patients with a more prominent gut dysfunction such as those with CIPO.
Furthermore, we found a significant decrease in the mean number of myenteric neurons/ganglion in CIPO tissues showing a high APOB immunoreactivity. This finding is reminiscent of severe hypoganglionosis 14 in the patients who were found to carry the RAD21 p.622Ala>Thr homozygous mutation in this study.
Based on our data, APOB48 expression (at serum and tissue levels) was increased homogeneously in sporadic and familial CIPO and therefore there is a possible correlation between this marker and the degree of neuronal loss or undetectable symptom severity. Further studies eagerly are awaited to clarify whether a correlation between APOB expression levels and neuronal/clinical CIPO phenotype exists.
The pathophysiological significance of the generalized APOB overexpression observed in sporadic CIPO, in which no mutation of RAD21 was identified, currently is unclear. Our previous studies suggested a role for APOB in the molecular pathways required for enteric neuron development and survival. 16 Therefore, APOB48 increase may be activated as a compensatory effect of an abnormal/ defective enteric nervous system occurring in CIPO. We still do not know the precise temporal origin of the defect that leads to CIPO in patients with RAD21 mutations. The observed transcriptional down-regulation of runx1, which likely is relevant in early neuronal progenitors, possibly in the crest, argues for a migratory defect. At the same time, the observed loss of APOB suppression might be more relevant to neuronal progenitors in the gut itself ( Figure 6 ). Further studies of patients and conditional mouse mutants will be required to understand the potential relative contribution of different sites to CIPO pathology. Likewise, further research will be required to elucidate the factors contributing to the specific APOB48 overexpression and its clinical value in the management of CIPO patients. Nonetheless, our data inform the molecular aspects underlying the pathogenesis of CIPO and lead to the identification of a candidate biomarker, namely APOB48 overexpression, for this severe disabling gut dysmotility disorder.
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Supplementary Materials and Methods
Familial Turkish CIPO patients
The 2 brothers and sister, aged 26, 28, and 30 (IV-9, IV-10, and IV-11) ( Figure 1A ) presented with recurrent abdominal pain and pseudo-obstruction since childhood.
The proband IV-10 presented with episodes suggestive of intestinal obstruction since childhood (age, 11 y) and underwent repeated abdominal surgeries, although extensive investigation failed to detect any structural obstacle to transit. Endoscopic evaluation of the esophagus showed a long-segment Barrett esophagus extending up to 18 cm, and no evident abnormalities in the stomach. Esophageal manometry showed aperistalsis and undetectable lower esophageal pressures, and barium small-bowel enema showed megaduodenum and delayed emptying. The patient died at 29 years of age from complications of a surgical procedure prompted by intestinal perforation, while he was on total parenteral nutrition.
His brother (IV-9) had a similar long-lasting history of multiple hospitalizations and surgical procedures owing to recurrent subocclusive episodes. He presented virtually identical findings at upper-gastrointestinal endoscopy and esophageal manometry. However, his clinical features also included otosclerosis, glaucoma, and epilepsy. Cardiac abnormalities included pulmonary and tricuspid valve insufficiency. Their sister, IV-11, is a 30-year-old woman with an apparently milder form of CIPO characterized only by sporadic radiologically confirmed subocclusive episodes (ie, air-fluid levels in distended bowel loops). Digestive symptoms were associated with malnutrition and amenorrhea. Endoscopy showed long-segment (up to 14 cm) Barrett esophagus, intragastric bezoars, and megaduodenum. Functional tests provided results similar to those observed in her affected brothers, namely delayed gastric emptying and severe dysmotility (ie, aperistalsis with simultaneous contractions, undetectable lower esophageal sphincter pressure) at esophageal manometry. A male and female cousin, also born of consanguineous parents, were reported to have gastrointestinal complaints and died at 19 and 15 years of age, respectively. The female cousin who died at age 15 had clinical and radiologic evidence of CIPO, as well as renal hypoplasia, vesico-ureteral reflux, ascites, and unspecified granulomatous hepatitis.
High-Throughput SNP Genotyping
A total of 400 ng of genomic DNA from peripheral blood was used for high-throughput SNP genotyping on an Illumina Infinium HD Assay Gemini platform (Illumina, San Diego, CA), according to the manufacturer's protocol. Genotypes were converted into PLINK format with custom scripts. PLINK v1.07 (http://ngu.mgh.harvard.edu/ wpurcell/plink/) was used to isolate individual runs of homozygosity that showed more than 1 Mb overlap between the 3 affected siblings.
Whole-Exome Sequencing Analysis
A total of 1 mg of genomic DNA was subjected to a series of shotgun library construction steps, including fragmentation through acoustic sonication (Covaris, Woburn, MA), end-polishing and A-tailing, ligation of sequencing adaptors, and PCR amplification with 8-bp barcodes for multiplexing. Libraries underwent exome capture using the Roche/Nimblegen SeqCap EZ v3.0 (w62 MB target) (Roche, Basel, Switzerland). Library quality was assessed by triplicate quantitative PCR and molecular weight distributions were verified on the Agilent Bioanalyzer (consistently 125 ± 15 bp). Pooled, barcoded libraries were sequenced via paired-end 50-bp reads with an 8-bp barcode read on Illumina HiSeq2000/2500 sequencers (Illumina). Unaligned binary format of sequence files (BAM) files were aligned to a human reference (hg19) using the Burrows-Wheeler Aligner (v0.6.2). Read data from a flowcell-lane were treated independently for alignment and quality control purposes before merging data to complete an exome. Sample-level quality control was performed on merged data after it had met the threshold for coverage metrics on exome target. Read-pairs not mapping within ± 2 standard deviations of the average library size (w125 ± 15 bp for exomes) were removed. All aligned read data were subject to the following steps: (1) removal of duplicate reads using Picard MarkDuplicates v1.70; (2) indel realignment with the Genome Analysis Toolkit (https:// www.broadinstitute.org/gatk/) IndelRealigner v1.6-11-g3b2fab9; and (3) base qualities recalibration with Genome Analysis Toolkit Table Recalibration, variants were flagged using the filtration walker (Genome Analysis Toolkit) to mark sites that were of lower quality or false positives (eg, low-quality scores [Q50], allelic imbalance [ABHet, 0.75], long homopolymer runs > 3, and/or low quality by depth < 5). Variants were annotated with the SeattleSeq137 Annotation Server (http://gvs.gs.washington. edu/SeattleSeqAnnotation).
RAD21 Mutation Screening in Sporadic CIPO Patients
PCR primers for human RAD21 (NM_006265.2) were designed with Primer3 v4.0 (http://primer3.ut.ee) and are available on request. Genomic DNA extracted from peripheral blood was amplified according to the following PCR conditions: 30 ng of DNA, 2.5 mmol/L MgCl 2 , 0.5 mmol/L deoxynucleoside triphosphate, 0.5 mmol/L primers, 5% dimethyl sulfoxide in a final volume of 20 mL using the 2X KAPA Fast Taq Polymerase Master mix (KAPA Biosystems, Wilmington, MA). Forty cycles were performed as follows: 95 C 1 0 , 95 C 15 00 , 58 C 1 00 , and 72 C 1 00 , with a final extension of 30 00 at 72 C. PCR products were purified onto Millipore PCR clean-up plates (Millipore, Darmstadt, Germany) and directly sequenced on both strands using the BigDye v1.1 kit (Life Technologies, Carlsbad, CA). Electropherograms were visualized with Chromas version 2.0 (Chromas, Technelysium, South Brisbane, Australia) and Sequencer version 4.7.
(OriGene, Rockville, MD). The mutation corresponding to p.622 Ala>Thr was inserted by site-directed mutagenesis using the QuickChange XL mutagenesis kit (Agilent Technologies, Santa Clara, CA) according to the manufacturer's instructions. The insertion of the changes was verified by direct sequencing. HEK293 human renal cells (3 Â 10 5 ; ATCC, Middlesex, UK) were plated for transfection of the different plasmids using liposomes according to the manufacturer's instructions (Lipofectamine; Life Technologies). Protein and RNA extraction was performed after 48 hours from transfection.
Gene Expression Analysis
Total RNA from 1.5 mL fresh blood was extracted with the Qiagen Blood Total RNA kit (Qiagen). Total RNA from 5 Â 10 6 LCLs or HEK293 cells, cultured according to standard protocols, was extracted with the RNeasy kit (Qiagen). A total of 1 mg of DNase I-treated RNA was used for reverse transcription with random hexamers using the Multiscribe RT system (Life Technologies) at 48 C for 40 0 in a final volume of 50 mL. Quantitative RT-PCR was performed with SYBRGreen, 0.5 mmol/L primers, in an ABI 7500 Real-Time PCR System (Life Technologies). All target genes were normalized with the corresponding endogenous control (b-actin) using the DDCt comparative method. PCR primers are available on request.
Immunoprecipitation and Western Blotting
A total of 2 Â 10 6 LCLs were lysed in 50 mmol/L HEPES, 1 mmol/L EDTA, 10% glycerol, 1% Triton X-100, and 150 mmol/L NaCl in the presence of protease inhibitors (Roche Diagnostics, Basel, Switzerland), and phosphatase inhibitors (Inhibition Cocktails 2 and 3; Sigma). Preclearing was performed with rabbit IgG (Millipore) for 1 hour at 4 C. Immunoprecipitation assays were performed at 4 C using 0.8 mg rabbit anti-SMC1 or anti-RAD21 antibody/reaction (Sigma Prestige) on Protein G-Sepharose (Sigma). Proteins were separated by sodium dodecyl sulfate gel electrophoresis, transferred onto a nitrocellulose membrane (GE Healthcare, Little Chalfont, UK), and subjected to Western blot with the Western Breeze kit (Life Technologies). Proteins extracted from sera of patients were diluted 1:5 in phosphate-buffered saline, quantified with the Lowry method and Coomassie Blue gel staining, separated by sodium dodecyl sulfate gel electrophoresis, and transferred onto a nitrocellulose membrane (GE Healthcare). Primary antibodies used were as follows: goat anti-APOB48 1:250 (Santa Cruz, Dallas, TX), goat anti-APOB 1:1000 (Dako, Santa Clara, CA), rabbit anti-APOB100 1:200 (Abcam, Cambridge, UK), and mouse anti-glyceraldehyde-3-phosphate dehydrogenase (Abcam) diluted at 1:5000. Bands were visualized using the enhanced chemoluminescence method (GE Healthcare).
Zebrafish Functional Assays
To determine the effect of rad21a suppression in zebrafish embryos, a splice-blocking morpholino was designed by Gene Tools, LLC (Philomath, OR), rad21a MO (AGGGTCTGCGTTCCTTGACTTCCAT), targeting the splice junction at the 3' end of exon 2. A published ret MO (ACACGATTCCCCGCGTACTTCCCAT) was used. 20 To measure rad21a MO efficiency, total mRNA was extracted from control and MO-injected embryos, reverse-transcribed, and the site targeted by the MO was PCR-amplified using the following primers: GGGACAAAAAGCTGACCAAA and CAGGGTGAACTGCTGTGCTA.
For knockdown and rescue experiments, we injected either 3 ng of rad21 MO (runx1 expression), or 1.2 ng rad21 MO (gut phenotype). For zebrafish injections, capped human RAD21 mRNA was produced by cloning wild-type RAD21 cDNA and the 3 mutant constructs (P376R, C585R, and A622T) into the pCS2þ expression vector and reverse transcribing each construct in vitro with the SP6 Message Machine kit (Ambion, Austin, TX).
Injected embryos were fixed at 5 dpf in 4% paraformaldehyde for 16 hours at 4 C, and moved to methanol at -20 C. After rehydration steps in decreasing series of methanol/PBS containing 0.1% Tween-20, permeabilization, postfixation, and blocking, embryos were incubated with anti-HuC/D antibody (1:500; Life Technologies) for 16 hours at 4 C. After washes in PBT, embryos were incubated with Alexa-488 (1:500; Invitrogen, Carlsbad, CA) as a secondary antibody. All experiments were repeated 3 times and the Pearson chi-square test was used to determine significance.
For in situ analysis, a runx1 probe was designed using the following primers: AATTAACCCTCACTAAAGGGGC CACTGCAAGCACCTCTGG and TAATACGACTCACTATAGGA CGAGGAGAGGACACAAAGC. Digoxigenin-labeled antisense probe was synthesized using T7 from a plasmid kindly provided by Kathryn Crosier. Injected embryos (w14 dpf) were fixed in 4% paraformaldehyde for 16 hours at 4 C, and moved to 100% methanol for storage. After step-wise rehydration washes, embryos were incubated at 65 C with the runx1 probe. Antidigoxigenin antibodies conjugated with alkaline phosphatase antibody were used and developed with nitro blue tetrazolium (NBT)/5-bromo-4-chloro-3-indolyl-phosphate (BCIP) as substrate. For supershift assay, nuclear extracts were incubated at the same conditions as reported earlier, but the complexes were immunoprecipitated for 40 minutes at 4 C with 1.5 mg of rabbit anti-RAD21 antibody (Abcam) before the electromobility shift assay assays. Complexes were resolved under nondenaturing conditions using a 3.5% polyacrylamide gel. 
Electromobility Shift Assay
Immunohistochemistry
Immunohistochemistry was performed on paraffinembedded adult human colon tissues (patients routinely underwent surgery for uncomplicated colon cancers commonly were used as controls for immunohistochemical experiments) according to protocols validated in our laboratory. Briefly, tissue sections were treated to remove paraffin embedding by 3 sequential washes in xylene and graded ethanol. Antigen unmasking was performed by heating sections at 95 C in 10 mmol/L sodium citrate buffer, pH 6.0, for 10 minutes, and subsequent cooling at room temperature for 30 minutes. To reduce endogenous peroxidases, tissue sections were treated with an ad hoc blocking kit (GeneTex, Inc, Irvine, CA) and incubation for 16 hours at 4 C with primary antibodies. The following primary antibodies were used: anti-human APOB48 (Santa Cruz) and anti-human APOB diluted 1:100 (Abcam); and anti-human RAD21 diluted 1:250 (Sigma Prestige) and antihuman APOBEC1 diluted 1:100 (Creative Diagnostics, Bristol, UK). Incubations with the corresponding blocking peptides or with the secondary antibodies were performed only as negative controls ( Supplementary Figure 2A and B) . Fluorescent secondary antibodies were diluted 1:300 in Triton-X and incubated for 60 minutes at room temperature before subsequent dehydration and visualization under a Leica DMLB fluorescent microscope (Leica, Mannheim, Germany). 3,3
0 -diaminobenzidine tetra hydrochloride staining was performed according to standard protocols.
Quantitative Evaluation of Ganglion Cells
We counted the number of neurons after immunostaining with a rabbit polyclonal anti-human neuronalspecific enolase antibody 1:400 (Millipore). For each section, 25-28 high-power (40Â) microscopic fields, along the neuromuscular ridge of the myenteric ganglia, were captured to assess neuronal-specific enolase immunoreactive neuronal cell bodies/ganglion. 22 The same procedure was performed for counting the neurons in the submucosal ganglia. Sections were examined using a Leica microscope equipped with a digital camera. Figure 4C ). (F) Electromobility shift assay analysis showing that LCL nuclear extracts containing either RAD21 wild-type or mutant protein retain the binding ability for the AC2 site on chromosome 11. Black arrows indicate the gel shifts. ITA_CIPO08  M  158  59  ITA_CIPO27  F  154  64  ITA_CIPO37  F  150  53  ITA_CIPO23  M  200  42  ITA_CIPO38  F  168  80  ITA_CIPO29  M  202  49  ITA_CIPO39  F  142  41  ITA_CIPO26  F  181  51  ITA_CIPO24  F  198  48  ITA_CIPO16  F  150  52  ITA_CIPO14  F  200  53  ITA_CIPO33  M  126  25  ITA_CIPO30  F  201 
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